Delivering neuroprotective antibodies to the brain for Alzheimer's disease treatment
Official title: CD98hc Brain Shuttles for Delivering Off-the-shelf Neuroprotective Antibodies in Alzheimer's Disease
Funded at University of Michigan at Ann Arbor · NIH-11249053 · Data updated 2026-11-12
This study is exploring a new way to help deliver special antibodies into the brains of people with Alzheimer's disease, which could lead to better treatments for the condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | April 1, 2023 |
| Project end | December 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $94,262 |
| NIH project number | 3R01AG080016-03S1 |
| Project ID | NIH-11249053 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults aged 65 and older who are experiencing symptoms of Alzheimer's disease.
✕Less likely to help
Patients under the age of 65 or those without Alzheimer's disease may not benefit from this research.
What this research studies
This research investigates a novel method to deliver neuroprotective antibodies across the blood-brain barrier for patients with Alzheimer's disease. The approach involves using a bispecific antibody shuttle that targets CD98hc, which may enhance the transport of these antibodies into the brain. By optimizing the characteristics of this shuttle and evaluating its effectiveness in animal models, the research aims to improve treatment options for Alzheimer's patients. If successful, this could lead to more effective therapies that address the underlying causes of the disease.
Why it matters
Potential benefit: If successful, this research could provide a new way to deliver effective treatments for Alzheimer's disease, potentially improving patient outcomes.
How similar studies have gone: Previous research has shown promise in using targeted delivery methods for biologics, but this specific approach using CD98hc is relatively novel.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Tessier, Peter M — University of Michigan at Ann Arbor
- Study coordinator: Tessier, Peter M
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.